Board of Directors

Mr. Jian Hua has served as the CEO and a director of our Company since January 2024 and May 2024, respectively. He has also served as the chairman of our board of directors since November 2024. With over 20 years of experience in the research and development as well as enterprise operation and management in multi-disciplinary positions, Mr. Hua has an in-depth and thorough understanding of biology, medical devices, and healthcare industries. He currently also serves as the chairman of the board of Shenzhen Feellife and Shenzhen LFS, which he founded, since January 2013 and September 2009, respectively. In addition, Mr. Hua joined Shenzhen Topsee Industrial Co., Ltd., a National Equities Exchange and Quotations (“NEEQ”) listed company (stock code: 832042) in China in 2006, where he has served as a director and the general manager from November 2006 to February 2022 and from November 2006 to January 2022, respectively. Mr. Hua is an experienced technical expert and owns more than 20 patents. Mr. Hua received the degree of master of business administration from Dalian University of Technology in China in 2018, the degree of doctorate of business administration in management (DBA) from INSEEC Business School in France in 2015, the diploma of professional doctorate in applied economics from University of Versailles in France in 2014.

Ms. Lina Song has served as a director and chief technology officer of our Company since May 2024. Ms. Song has more than 20 years of working experience in chemical industry and inhalation industry. She has also served as a director and the general manager of Shenzhen Feellife since September 2009. Ms. Song served as the testing supervisor of Hengchan Coating Co., Ltd. from November 2004 to August 2009. Prior to that, Ms. Song served as a chemical analysist at Guangdong Zhaoqing Sapphire Rare Metal Co., Ltd. from June 2003 to October 2004. Ms. Song obtained the bachelor’s degree in chemical engineering and process from Central South University in China in 2003.

Ms. Fei Xu has served as a director and the general manager of our Company since May 2024 and July 2016, respectively. Ms. Xu has more than 20 years of working experience in chemical industry and inhalation industry. She has also served as the general manager of Shenzhen LFS since July 2016. Ms. Xu served as a financial manager of Shenzhen Topsee Industrial Co., Ltd. from July 2015 to June 2016. Prior to that, Ms. Xu served as a financial manager of Shenzhen Jason Digital Technology Co., Ltd from March 2012 to June 2015. Ms. Xu obtained the bachelor’s degree in accounting from Shenzhen Open University in China in 2009 and has been studying in business administration in Tsinghua Shenzhen International Graduate School in China since August 2022.

Mr. Joel Adalberto Gallo, our independent director, has worked in the fields of global banking, capital markets, asset management and technology for approximately 25 years. Mr. Gallo is currently the CFO of HD EDU in Shenzhen, China. He is also currently an independent director of Santech Holding, serving on Santech’s audit committee. From February 2021 to May 2023, Mr. Gallo served as the CFO of ETAO International Group. From April 2013 to December 2018, he co-founded and served as the principal of GLS Group LLC. From January 2011 to March 2013, he served as the director of financial services of Pricewaterhouse Coopers. Mr. Gallo holds a bachelor of science degree in management from Binghamton University, a master of arts degree in international relations from Tufts University, and a master of public administration degree from Columbia University. Mr. Gallo is also currently an adjunct professor in New York University — Shanghai and Shanghai University of Finance and Economics.

Mr. Douglas Bruce Noyes, our independent director, has served in several managerial positions in the manufacturing industry for approximately 33 years. He is currently the director of manufacturing & continuous improvement at PCI, a company in the aerospace/defense, medical, commercial, and oil & gas industries. From June 2012 to November 2022, he served as the director of global operations of OK International. From December 2009 to May 2012, he served as the director of manufacturing of Quallion LLC. From December 2008 to November 2009, Mr. Noyes served as the interim director of operations at Anodyne Medical. From February 2006 to November 2008, he served as the general manager of Phillips Industries. Mr. Noyes holds a bachelor of arts degree in business administration.

Mr. Peter Shihkai Su, our independent director, has served in the banking field for 18 years in a managerial capacity. He is currently the director of specialty banking in Hanover Bank, being responsible of for all aspects of launching a de novo cannabis program working with internal and external stakeholders. From November 2021 to April 2023, he served as the national relationship manager of Green Check Verified, during which he consulted with financial institutions around the United States. From June 2021, Mr. Su served as the first vice president of East West Bank. From July 2019 to June 2021, he served as the vice president of the Dume Community (BNB) Bank. Mr. Su holds a bachelor’s degree from Stony Brook University.

Dr. James Jiayuan Tong, our independent director, has worked in managerial and directorial capacities in the finance and investment sector for approximately 18 years. Dr. Tong led the strategic developments of ThorBay Holdings as its founder, specializing on alternative investments, pre-IPO strategies, healthcare innovations, modernized farming assets development, automation and operation. He is also currently serving as the board director and the chair of the compensation committee of Horizon Space II, a special purpose acquisition corporation. From September 2019 to February 2022, Dr. Tong served as the director and the venture partner of Korean Investment Partners. From September 2016 to June 2019, Dr. Tong served as the chief executive officer and the director of Bison Capital Acquisition Corp, US. Earlier in his career, Dr. Tong held multiple executive positions as a venture partner and chief financial officer in public and private companies. Dr. Tong also specializes in hospital development and management. Dr. Tong’s experience covers corporate finance, SEC compliance, cross-border mergers and acquisitions. Dr. Tong earned his M.D. from Peking University Health Science Center in 1996 and Ph.D. in Neurobiology and Behavior from Cold Spring Harbor Laboratory and Stony Brook University in 2001.